Scienture Holdings, Inc.

Scienture Holdings, Inc. is a pharmaceutical company that develops and sells products for central nervous system and cardiovascular diseases in the United States. The company is developing SCN-102, an oral liquid formulation of losartan potassium, which is currently in Phase 1 trials. SCN-102 is intended to treat hypertension, diabetic nephropathy, and reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy. Scienture Holdings also develops SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. Additionally, the company is working on SCN-106, a thrombolytic agent designed to bind to fibrin in clots and convert entrapped plasminogen to plasmin. Another product in development is SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional pain relief. Scienture Holdings, Inc. is headquartered in Commack, New York.